EGFR

Biomarkers

EGFR is involved in the following curated biomarkers.

Name	Biomarker type	Propositions	Statements
EGFR Exon 20 (Insertion)	Somatic Variant	5	7
EGFR activating variants	Somatic Variant	1	1
EGFR Exon 19 (Deletion)	Somatic Variant	10	21
EGFR p.L858R	Somatic Variant	10	21
EGFR somatic variants	Somatic Variant	3	4
EGFR p.T790M	Somatic Variant	2	3
Wild type EGFR	Wild type	27	40
EGFR TKD activating variants	Somatic Variant	1	1

Therapeutic response

Precision oncology relationships for therapeutic response involving this gene.

Organization(s)	Biomarker(s)	Cancer type	Therapy(ies)
FDA (1) HC (1)	EGFR Exon 20 (Insertion)	Non-Small Cell Lung Cancer	Amivantamab, Carboplatin, Pemetrexed
FDA (1) HC (1)	EGFR Exon 20 (Insertion)	Non-Small Cell Lung Cancer	Amivantamab
FDA (1)	EGFR Exon 20 (Insertion)	Non-Small Cell Lung Cancer	Mobocertinib
FDA (1)	EGFR Exon 20 (Insertion)	Invasive Breast Carcinoma	Datopotamab deruxtecan
FDA (1)	EGFR Exon 20 (Insertion)	Non-Small Cell Lung Cancer	Sunvozertinib
HC (1)	EGFR activating variants	Non-Small Cell Lung Cancer	Afatinib
FDA (1)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Dacomitinib
FDA (1)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Erlotinib
FDA (1) HC (1)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Gefitinib
FDA (3) HC (3)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Osimertinib
FDA (1) HC (1)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Carboplatin, Osimertinib, Pemetrexed
FDA (1) HC (1)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Cisplatin, Osimertinib, Pemetrexed
FDA (1)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Erlotinib, Ramucirumab
FDA (2) HC (1)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Amivantamab, Lazertinib
FDA (1) HC (1)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Amivantamab, Carboplatin, Pemetrexed
FDA (1)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Datopotamab deruxtecan
FDA (1)	EGFR p.L858R	Non-Small Cell Lung Cancer	Dacomitinib
FDA (1)	EGFR p.L858R	Non-Small Cell Lung Cancer	Erlotinib
FDA (1) HC (1)	EGFR p.L858R	Non-Small Cell Lung Cancer	Gefitinib
FDA (3) HC (3)	EGFR p.L858R	Non-Small Cell Lung Cancer	Osimertinib
FDA (1) HC (1)	EGFR p.L858R	Non-Small Cell Lung Cancer	Cisplatin, Osimertinib, Pemetrexed
FDA (1) HC (1)	EGFR p.L858R	Non-Small Cell Lung Cancer	Carboplatin, Osimertinib, Pemetrexed
FDA (1)	EGFR p.L858R	Non-Small Cell Lung Cancer	Erlotinib, Ramucirumab
FDA (2) HC (1)	EGFR p.L858R	Non-Small Cell Lung Cancer	Amivantamab, Lazertinib
FDA (1) HC (1)	EGFR p.L858R	Non-Small Cell Lung Cancer	Amivantamab, Carboplatin, Pemetrexed
FDA (1)	EGFR p.L858R	Non-Small Cell Lung Cancer	Datopotamab deruxtecan
FDA (1) HC (1)	EGFR somatic variants	Non-Small Cell Lung Cancer	Afatinib
FDA (1)	EGFR somatic variants	Non-Small Cell Lung Cancer	Atezolizumab
FDA (1)	EGFR somatic variants	Non-Small Cell Lung Cancer	Datopotamab deruxtecan
FDA (1) HC (1)	EGFR p.T790M	Non-Small Cell Lung Cancer	Osimertinib
FDA (1)	EGFR p.T790M	Non-Small Cell Lung Cancer	Datopotamab deruxtecan
FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel
FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab, Carboplatin, Paclitaxel
FDA (1) HC (1)	Wild type ALK, Wild type EGFR, Wild type ROS1	Non-Small Cell Lung Cancer	Carboplatin, Cemiplimab, Pemetrexed
FDA (1)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR, dMMR	Non-Small Cell Lung Cancer	Cemiplimab
FDA (2)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Pemetrexed, Tremelimumab
FDA (2)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Pemetrexed, Tremelimumab
FDA (2)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Gemcitabine, Tremelimumab
FDA (2)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Gemcitabine, Tremelimumab
FDA (2)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Nab-paclitaxel, Tremelimumab
FDA (1) HC (2)	PD-L1 >= 1%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Ipilimumab, Nivolumab
FDA (2)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Ipilimumab, Nivolumab, Pemetrexed
FDA (2) HC (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Ipilimumab, Nivolumab, Pemetrexed
FDA (2)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Nivolumab, Paclitaxel
FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Pembrolizumab, Pemetrexed
FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Pembrolizumab, Pemetrexed
FDA (1) HC (1)	PD-L1 >= 1%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Pembrolizumab
FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Paclitaxel
FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Gemcitabine
FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Pemetrexed
FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Pemetrexed
FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Nivolumab, Pemetrexed
FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Gemcitabine, Nivolumab
HC (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Tremelimumab
HC (1)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR, Wild type ROS1	Non-Small Cell Lung Cancer	Cemiplimab
HC (1)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab
HC (1)	PD-L1 >= 10% TIIC, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab
HC (1)	EGFR TKD activating variants	Non-Small Cell Lung Cancer	Gefitinib